ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation
2024年10月31日 · ICER provides independent evaluations on the value of medical tests, treatments and delivery systems
About Us | Institute for Clinical & Economic Review - ICER
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests.
What is ICER | Institute for Clinical & Economic Review
Founded in 2006 and non-profit incorporated in 2013, ICER has become the nation’s non-partisan, independent, go-to-resource for objective evidence about the value of health care in the U.S. ICER’s appraisals of more than 100 drugs for more than 50 medical conditions, in addition to multiple devices and diagnostics, have demonstrated that ...
Methods & Process | Our Approach - ICER
How We Do Our Work. ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health care system know what works. ICER has a developed a Value Assessment Framework, which is the foundation of our work.
Leadership Staff | Who We Are - ICER
Meet ICER's leadership team and staff. Read individual bios of members of the ICER team, from the president to researchers.
Press Releases | News & Insights - ICER
Subscribers can expect to receive press releases at the following milestones: Topic Announcement, Draft Evidence Report, Revised Evidence Report, and Final Evidence Report. You can also find the week’s press releases in our newsletter. For any questions, please contact [email protected].
Assessments | Explore Our Research - ICER
Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you.
Institute for Clinical and Economic Review Publishes ... - icer.org
2024年10月31日 · In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs.
Cost-Effectiveness, the QALY, and the evLYG - ICER
Clinicians play a vital role in helping individual patients decide what treatment is best for them. In contrast, cost-effectiveness analysis looks at evidence for entire patient populations, comparing the health benefits and economic costs of different treatment options.
ICER Publishes Final Evidence Report on Lecanemab for …
BOSTON, April 17, 2023 – The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of lecanemab (Leqembi, Eisai Inc.) for the treatment of Alzheimer’s disease.